within Pharmacolibrary.Drugs.ATC.L;

model L01BC07_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.89,
    Cl             = 167 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 75 / 1000000,
    adminCount     = 1,
    Vd             = 0.076,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.043333333333333335,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Azacitidine is a nucleoside metabolic inhibitor with antineoplastic activity, primarily used in the treatment of myelodysplastic syndromes (MDS) and certain types of acute myeloid leukemia (AML). It acts by incorporation into DNA and RNA, resulting in cytotoxicity and inhibition of DNA methyltransferase. Azacitidine is approved for clinical use and is currently used in therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with myelodysplastic syndromes after subcutaneous administration of azacitidine.</p><h4>References</h4><ol><li><p>Du, X, et al., &amp; Beach, CL (2018). Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. <i>Asia-Pacific journal of clinical oncology</i> 14(3) 270–278. DOI:<a href=&quot;https://doi.org/10.1111/ajco.12835&quot;>10.1111/ajco.12835</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29282890/&quot;>https://pubmed.ncbi.nlm.nih.gov/29282890</a></p></li><li><p>Chou, WC, et al., &amp; Beach, CL (2017). Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes. <i>Asia-Pacific journal of clinical oncology</i> 13(5) e430–e439. DOI:<a href=&quot;https://doi.org/10.1111/ajco.12659&quot;>10.1111/ajco.12659</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28124500/&quot;>https://pubmed.ncbi.nlm.nih.gov/28124500</a></p></li><li><p>Laille, E, et al., &amp; Beach, CL (2014). A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment. <i>Pharmacotherapy</i> 34(5) 440–451. DOI:<a href=&quot;https://doi.org/10.1002/phar.1371&quot;>10.1002/phar.1371</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24877181/&quot;>https://pubmed.ncbi.nlm.nih.gov/24877181</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01BC07_1;
